血脂康通过AMPK/eNOS对糖尿病肾病大鼠的肾脏保护作用OA

Objective To investigate the renoprotective effect of Xuezhikang in rats with diabetic kidney disease(DKD),via AMP-activated protein kinase(AMPK)/endothelial nitric oxide synthase(eNOS)pathway.Methods SD rats were divided randomly into five groups:control,DKD model,Xuezhikang(DKD modeling+1 200 mg/(kg·d)Xuezhikang by gavage),inhibitor group(DKD modeling+0.2 mg/(kg·d)AMPK inhibitor Compound C by intraperitoneal injection),and Xuezhikang+inhibitor(DKD modeling+1 200 mg/(kg·d)Xuezhikang by gavage+0.2 mg/(kg·d)AMPK inhibitor Compound C by intraperitoneal injection).Renal pathological changes,renal function indicators(24-hour urine albumin,serum creatinine(Scr),blood urea nitrogen(BUN)),expression levels of phosphorylated AMPK(p-AMPK)and eNOS,and levels of inflammatory indicators(tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)),oxidative stress indicators(superoxide dismutase(SOD)and malondialdehyde(MDA))in the kidneys were detected after 4 weeks of the respective interventions.Results Compared with the model group,renal pathological changes were alleviated,levels of 24-hour urinary albumin,Scr,BUN,TNF-α,IL-6,and MDA in the kidneys decreased,while expression levels of p-AMPK,eNOS,and SOD increased in the Xuezhikang group(P＜0.05).In addition,renal pathological changes were aggravated,levels of 24-hour urinary albumin,Scr,BUN,TNF-α,IL-6,and MDA in the kidneys increased,while expression levels of p-AMPK,eNOS,and SOD decreased in the inhibitor group(P＜0.05).Compared with the Xuezhikang group,renal pathological changes were aggravated,levels of 24-hour urinary albumin,Scr,BUN,TNF-α,IL-6,and MDA in the kidneys increased,while expression levels of p-AMPK,eNOS,and SOD decreased in the Xuezhikang+inhibitor group(P＜0.05).Conclusions Xuezhikang alleviates renal injury and the inflammatory and oxidative stress responses in DKD rats by activating AMPK/eNOS.